-
公开(公告)号：US20190203195A1
公开(公告)日：2019-07-04
申请号：US16228763
申请日：2018-12-21
发明人： Cheng-Tai Chen , Chien-An Chen , Wen-Ting Chiang , Su-Feng Chiu , Pei-Shin Jiang , Jih-Luh Tang , Chien-Ting Lin , Xuan-Hui Lin
CPC分类号： C12N13/00 , C12N5/0634 , C12N5/0636 , C12N2501/505 , C12N2501/515 , C12N2501/998 , C12N2529/00 , C12N2533/10 , C12N2533/30 , C12N2535/00 , C12N2535/10 , G01N33/54333
摘要： A method for in vitro activation and/or expansion of immune cells is provided, including the steps of: a) providing magnetic particles having multi-protrusive surface modified with at least one type of immuno-inducing substance, in which each magnetic particle includes a copolymer core, a polymer layer, a magnetic substance layer, and a silicon-based layer from the inside to the outside; b) providing a cell solution including at least one type of immune cell in the cell solution; and c) bringing the magnetic particles in contact with the cell solution, in which the at least one type of immuno-inducing substance on the surface of the magnetic particle activates and/or expands the at least one type of immune cell in the cell solution.
-
公开(公告)号：US10077426B2
公开(公告)日：2018-09-18
申请号：US14401524
申请日：2013-12-05
发明人： Dror Mevorach , Inna Reiner
IPC分类号： A61K31/727 , C12N5/00 , C12N5/078 , A61K35/17 , A61K45/06 , A61K31/194 , A61K31/573 , A61K31/7004
CPC分类号： C12N5/0634 , A61K31/194 , A61K31/573 , A61K31/7004 , A61K31/727 , A61K35/17 , A61K45/06 , A61P37/00 , A61K2300/00
摘要： The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (GVHD) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis.
-
公开(公告)号：US20180216065A1
公开(公告)日：2018-08-02
申请号：US15746773
申请日：2016-07-20
发明人： Tai Gyu KIM , Mi Young PARK
IPC分类号： C12N5/078 , C12N5/0775
CPC分类号： C12N5/0634 , A61K35/15 , A61P37/06 , C12N5/0665 , C12N2501/125 , C12N2501/22 , C12N2506/115
摘要： The present invention relates to a method for inducing differentiation myeloid-derived suppressor cells from cord blood CD34 positive cells and proliferating the same, and a use of the myeloid-derived suppressor cells. More specifically, myeloid-derived suppressor cells are induced to differentiate and proliferated by culturing cord blood CD34 positive cells in the presence of a cytokine cocktail of GM-CSF and SCF, such that myeloid-derived suppressor cells can be mass-produced in vitro, and the myeloid-derived suppressor cells can be used in preventing or treating immunorejection-related diseases such as graft-versus-host disease.
-
公开(公告)号：US20180168142A1
公开(公告)日：2018-06-21
申请号：US15579102
申请日：2016-05-13
申请人： Fenwal, Inc.
CPC分类号： A01N1/0226 , A61K35/14 , A61M1/0281 , A61M1/3609 , A61M1/3692 , A61M1/3693 , C12N5/0634
摘要： A system for washing red blood cells, comprising a separator configured to separate a quantity of blood into concentrated red blood cells having a hematocrit of at least 60% and a volume of 150-250 mL, and a supernatant component. The system comprises a flow controller configured to remove the supernatant component to provide an initial red blood cell concentrate; combine 50-500 mL of an additive solution with the red blood cell concentrate to provide an intermediate red blood cell product intended for storage for 42 days or less, wherein the intermediate red blood cell product at the end of storage has an osmolarity value between 202-479 mOsm/L; and wash the intermediate red blood cell product comprising the osmolarity value between 202-479 mOsm/L with a washing solution having an osmolarity value higher than that of the intermediate red blood cell product comprising the osmolarity value between 202-479 mOsm/L.
-
公开(公告)号：US20180133257A1
公开(公告)日：2018-05-17
申请号：US15572106
申请日：2016-05-04
发明人： Hyo-Soo KIM , Jin HUR , Jae Il CHOI
CPC分类号： A61K35/28 , A61K38/17 , A61K2035/124 , A61P35/00 , C07K14/705 , C12N5/0081 , C12N5/0634 , C12N2502/1157 , C12N2502/1171
摘要： Provided is a KAI1 protein controlling the cell cycle of a hematopoietic stem cell and a use thereof, and more specifically, a composition including a KAI1(CD82) polypeptide or a gene encoding the same for controlling the cell cycle of a hematopoietic stem cell, or a pharmaceutical composition for preventing or treating blood tumors. Further provided, KAI1(CD82) is expressed only in a hematopoietic stem cell (LT-HSC) which is the uppermost stem cell in the hierarchy of the hematopoietic stem cell, can obtain an LT-HSC with high purity using the KAI1, and thus can inhibit various side effects of hematopoietic stem cell transplantation by transplanting only an LT-HSC with high purity. In addition, KAI1 importantly acts on the quiescence of an LT-HSC, and has resistance against cell damage due to various stresses (5-FU, irradiation, etc.) by maintaining the quiescence of the LT-HSC. Thus, it is expected that the cell can be used for making a cell bank and can be used as a blood tumor cell therapy product through cell transplantation.
-
公开(公告)号：US09944631B2
公开(公告)日：2018-04-17
申请号：US15635268
申请日：2017-06-28
发明人： Meyyappan Muthuppalaniappan , Srikant Viswanadha , Gayatri S. Merikapudi , Swaroop K. Vakkalanka
IPC分类号： C07D417/10 , A61K31/415 , A61K31/496 , A61K31/422 , A61K31/506 , A61K31/455 , A61K31/427 , A61K31/433 , C07D231/12 , C07D295/195 , C12N5/078 , A61K31/4439 , A61K31/5377 , A61K45/06 , C07D413/10 , C07D403/10 , C07D401/10 , C07D207/327 , C07D417/14 , C07D417/12 , C07D413/14 , C07D413/12 , C07D403/14 , C07D403/12 , C07D403/04 , C07D401/14 , C07D401/12 , C07D401/04 , C07D207/337
CPC分类号： C07D417/10 , A61K31/415 , A61K31/422 , A61K31/427 , A61K31/433 , A61K31/4439 , A61K31/455 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D207/327 , C07D207/337 , C07D231/12 , C07D295/195 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C12N5/0634 , C12N2500/46 , Y02A50/422
摘要： Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
-
公开(公告)号：US09943638B2
公开(公告)日：2018-04-17
申请号：US15337418
申请日：2016-10-28
申请人： Fenwal, Inc.
发明人： Kyungyoon Min , Richard I. Brown , John T. Foley , Brian C. Case
CPC分类号： A61M1/3693 , A61M1/3696 , A61M2205/128 , A61M2205/3331 , A61M2205/3337 , B04B5/0442 , B04B2005/045 , C12N5/0634 , C12N5/0641 , C12N5/0644
摘要： Centrifugation systems and methods are provided for separating blood into its constituent parts. Inner and outer walls of a centrifuge each include a projection which extends toward the other wall. A separation chamber is received in the centrifuge between the walls, with the chamber including an inlet port for flowing blood into the chamber, a plasma outlet port for flowing plasma out of the chamber, and a red cell outlet port for flowing red blood cells out of the chamber. With the chamber received in the centrifuge between the walls, the first projection extends into the path of separated blood components flowing toward the plasma outlet port and prevents cellular blood components from flowing into the plasma outlet port. The second projection extends into the path of separated blood components flowing toward the red cell outlet port and prevents plasma from flowing into the red cell outlet port.
-
公开(公告)号：US20170360907A1
公开(公告)日：2017-12-21
申请号：US15532740
申请日：2015-12-04
发明人： Jonathan Serody , James Coghill , Danny Bruce , Bruce Blazar , Heather Stefanski , Benjamin Vincent
CPC分类号： A61K39/001 , A61K35/17 , A61K35/28 , A61K2035/122 , A61K2035/124 , A61K2039/5154 , A61K2039/577 , C12N5/0634 , C12N5/0651 , C12N2501/2307 , C12N2501/2333 , A61K2300/00
摘要： ILC2 cells play a role in the pathogenesis of graft versus host disease (GvHD) and idiopathic pneumonia syndrome (IPS), both conditions associated with allogeneic stem cell transplantation. Infusion of IL-33 activated ILC2 cells into patients with ongoing GvHD or IPS, or prior to onset of GvHD or IPS in susceptible patients, substantially ameliorates the disease and improves survival.
-
公开(公告)号：US20170349875A1
公开(公告)日：2017-12-07
申请号：US15637573
申请日：2017-06-29
申请人： SynGen Inc.
发明人： Philip H. Coelho , William Busa , Jonathan Ellis
CPC分类号： C12M47/02 , A61M1/029 , A61M1/3693 , A61M1/3696 , A61M2202/0439 , A61M2205/12 , A61M2209/086 , B04B2013/006 , C12M23/44 , C12M27/02 , C12M29/00 , C12N5/0634 , G01N1/34
摘要： Disclosed herein are cell separation devices, methods and systems, as well as compositions and reagents for use in cell separation methods.
-
公开(公告)号：US09821111B2
公开(公告)日：2017-11-21
申请号：US15489968
申请日：2017-04-18
申请人： SynGen Inc.
发明人： Philip H. Coelho , William Busa , Jonathan Ellis
CPC分类号： C12M47/02 , A61M1/029 , A61M1/3693 , A61M1/3696 , A61M2202/0439 , A61M2205/12 , A61M2209/086 , B04B2013/006 , C12M23/44 , C12M27/02 , C12M29/00 , C12N5/0634 , G01N1/34
摘要： Disclosed herein are cell separation devices, methods and systems, as well as compositions and reagents for use in cell separation methods.
-
-
-
-
-
-
-
-
-
搜索结果
490 条记录 (耗时 0.038 秒)